Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors

Monoacylglycerolacetyltransferase-2 (MGAT2) is a potential target for the treatment of type II diabetes. We report here the optimisation of a series of MGAT2 inhibitors with regard to their potency and permeability. Improvements in permeability, as measured by increased flux in a Caco-2 assay, were achieved through substitution at the 9-position of the core. We propose that reduction of the NH hydrogen-bond donor strength was primarily responsible for these effects.

[1]  R. Coleman,et al.  Enzymes of glycerolipid synthesis in eukaryotes. , 1980, Annual review of biochemistry.

[2]  Robert V Farese,et al.  MGAT2, a Monoacylglycerol Acyltransferase Expressed in the Small Intestine* , 2003, The Journal of Biological Chemistry.

[3]  Peter W. Kenny,et al.  Prediction of hydrogen bond basicity from computed molecular electrostatic properties: implications for comparative molecular field analysis , 1994 .

[4]  Robert V Farese,et al.  Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding , 2009, Nature Medicine.

[5]  P. Coleman,et al.  Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein. , 2007, Bioorganic & medicinal chemistry letters.

[6]  Peter W. Kenny,et al.  Hydrogen Bonding, Electrostatic Potential, and Molecular Design , 2009, J. Chem. Inf. Model..

[7]  Malin Lemurell,et al.  Identification and design of a novel series of MGAT2 inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[8]  P. Artursson,et al.  Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Yongxin Han,et al.  Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents. , 2011, Bioorganic & medicinal chemistry letters.

[10]  M. Waring.  Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.

[11]  C. L. Yen,et al.  Deficiency of MGAT2 increases energy expenditure without high-fat feeding and protects genetically obese mice from excessive weight gain , 2011, Journal of Lipid Research.

[12]  Matthew P. Jacobson,et al.  Predicting and improving the membrane permeability of peptidic small molecules. , 2012, Journal of medicinal chemistry.

[13]  M. Waring.  Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.

[14]  Thomas J. Raub,et al.  How hydrogen bonds impact P-glycoprotein transport and permeability. , 2012, Bioorganic & medicinal chemistry letters.

[15]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.